secwatch.observer — SEC 8-K summary
======================================

Issuer:     Roivant Sciences Ltd. (ROIV)
CIK:        0001635088
Form:       8-K
Filed at:   2024-09-18T23:59:59+00:00
Accession:  0001140361-24-041344
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Roivant's Dermavant to be acquired by Organon for $1.2B
-------------------------------------------------------

- Organon (OGN) will acquire Dermavant, a Roivant (ROIV) subsidiary, for $1.2B in cash and milestone payments.
- Deal includes VTAMA cream (tapinarof) 1%, approved for plaque psoriasis in adults (May 2022).
- sNDA for atopic dermatitis under FDA review; PDUFA decision expected Q4 2024.
- VTAMA is a once-daily steroid-free topical with no safety label warnings or duration/BSA restrictions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124041344/0001140361-24-041344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1635088/000114036124041344/ef20036017_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-041344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer